- Home
- PHLT vs OLMA Comparison
PHLT vs OLMA Comparison
Compare PHLT & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHLT
- OLMA
- Stock Information
- Founded
- PHLT 1976
- OLMA 2006
- Country
- PHLT United States
- OLMA United States
- Employees
- PHLT N/A
- OLMA N/A
- Industry
- PHLT Other Consumer Services
- OLMA Biotechnology: Pharmaceutical Preparations
- Sector
- PHLT Consumer Discretionary
- OLMA Health Care
- Exchange
- PHLT Nasdaq
- OLMA Nasdaq
- Market Cap
- PHLT 612.2M
- OLMA 725.5M
- IPO Year
- PHLT N/A
- OLMA 2020
- Fundamental
- Price
- PHLT $7.73
- OLMA $9.52
- Analyst Decision
- PHLT Buy
- OLMA Strong Buy
- Analyst Count
- PHLT 2
- OLMA 6
- Target Price
- PHLT $7.88
- OLMA $23.33
- AVG Volume (30 Days)
- PHLT 756.0K
- OLMA 1.3M
- Earning Date
- PHLT 11-05-2025
- OLMA 11-11-2025
- Dividend Yield
- PHLT N/A
- OLMA N/A
- EPS Growth
- PHLT N/A
- OLMA N/A
- EPS
- PHLT N/A
- OLMA N/A
- Revenue
- PHLT $137,357,000.00
- OLMA N/A
- Revenue This Year
- PHLT $12.38
- OLMA N/A
- Revenue Next Year
- PHLT $10.09
- OLMA N/A
- P/E Ratio
- PHLT N/A
- OLMA N/A
- Revenue Growth
- PHLT 15.21
- OLMA N/A
- 52 Week Low
- PHLT $2.17
- OLMA $2.86
- 52 Week High
- PHLT $7.75
- OLMA $13.51
- Technical
- Relative Strength Index (RSI)
- PHLT 73.60
- OLMA 52.27
- Support Level
- PHLT $7.70
- OLMA $10.28
- Resistance Level
- PHLT $7.75
- OLMA $11.06
- Average True Range (ATR)
- PHLT 0.02
- OLMA 0.79
- MACD
- PHLT -0.04
- OLMA -0.25
- Stochastic Oscillator
- PHLT 62.50
- OLMA 23.16
About PHLT Performant Healthcare Inc. Common Stock
Performant Healthcare Inc provides solutions to payers in the healthcare industry to identify, prevent, and recover waste and improper payments by leveraging technology, analytics, and proprietary data assets.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.